C4 Therapeutics Inc
NASDAQ:CCCC
Intrinsic Value
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. [ Read More ]
The intrinsic value of one CCCC stock under the Base Case scenario is 20.71 USD. Compared to the current market price of 6.9 USD, C4 Therapeutics Inc is Undervalued by 67%.
Valuation Backtest
C4 Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CCCC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
C4 Therapeutics Inc
Current Assets | 271.2m |
Cash & Short-Term Investments | 253.7m |
Receivables | 11.8m |
Other Current Assets | 5.7m |
Non-Current Assets | 105.3m |
Long-Term Investments | 28m |
PP&E | 71.1m |
Other Non-Current Assets | 6.2m |
Current Liabilities | 42.8m |
Accounts Payable | 1.4m |
Accrued Liabilities | 23.8m |
Other Current Liabilities | 17.5m |
Non-Current Liabilities | 87.6m |
Other Non-Current Liabilities | 87.6m |
Earnings Waterfall
C4 Therapeutics Inc
Revenue
|
20.8m
USD
|
Operating Expenses
|
-159.8m
USD
|
Operating Income
|
-139m
USD
|
Other Expenses
|
6.5m
USD
|
Net Income
|
-132.5m
USD
|
Free Cash Flow Analysis
C4 Therapeutics Inc
CCCC Profitability Score
Profitability Due Diligence
C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CCCC Solvency Score
Solvency Due Diligence
C4 Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
C4 Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CCCC Price Targets Summary
C4 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CCCC is 18.87 USD with a low forecast of 7.07 USD and a high forecast of 63 USD.
Ownership
CCCC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CCCC Price
C4 Therapeutics Inc
Average Annual Return | -17.15% |
Standard Deviation of Annual Returns | 56.15% |
Max Drawdown | -98% |
Market Capitalization | 473.3m USD |
Shares Outstanding | 68 600 704 |
Percentage of Shares Shorted | 18.92% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one CCCC stock under the Base Case scenario is 20.71 USD.
Compared to the current market price of 6.9 USD, C4 Therapeutics Inc is Undervalued by 67%.